NCT01347866 is a clinical trial for patients with advanced cancers combining the PI3K/mTOR inhibitors (PF-04691502 & PF-05212384) with the MEK inhibitor (PD-0325901) or irinotecan. Here, PIK3CA is linked to cancer.